LMNX - GenMark Diagnostics Still Not Getting A Lot Of Love

I can understand why investors may be leery of GenMark (GNMK). Although management has done a much better job of late in hitting its own targets, that has certainly not always been the case. Worse, they’re a later entrant into the multiplex molecular diagnostics field, and both bioMerieux (BMXXY) and Luminex (LMNX) enjoy bigger footprints (particularly the former with its BioFire FilmArray platform. And if that weren’t all enough, as more multiplex MDx tests become available, it is likely that reimbursement will get more complicated (if not less generous).

Read more ...